Document is current
Any future updates will be listed below
-
Authors
Perneel, Jolien
Lastra Osua, Miranda
Alidadiani, Sara
Peeters, Nele
De Witte, Linus
Heeman, Bavo
Manzella, Simona
De Rycke, Riet
Brooks, Mieu
Perkerson, Ralph B.
Calus, Elke
De Coster, Wouter
Neumann, Manuela
Mackenzie, Ian R. A.
Van Dam, Debby
Asselbergh, Bob
Ellender, Tommas
Zhou, Xiaolai
Rademakers, Rosa https://orcid.org/0000-0002-4049-0863
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G081323N, 11M1622N, 11PGP24N)
National Institutes of Health (UG3 NS10387020)
The Bluefield Project to Cure FTD
Mayo Clinic (NIH P30 AG062677)
National Natural Science Foundation of China (82171404)
University of Antwerp Research Funds
Vlaams Instituut voor Biotechnologie
Neurosearch Antwerp
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 31 March 2025
First Online: 23 April 2025
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Rademakers is a member of the Scientific Advisory Board of Arkuda Therapeutics and receives invention royalties from a patent related to progranulin. Dr. Mackenzie is a member of the Scientific Advisory Board of Prevail Therapeutics and receives invention royalties from a patent related to progranulin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
